Αποτελέσματα Αναζήτησης
3 Ιαν 2022 · Outrage over the cost of insulin is driving drug-pricing reform. Industry must do more to support patients dealing with spiraling out-of-pocket costs for biotech medicines.
- Metrics
We would like to show you a description here but the site...
- Metrics
14 Ιουν 2023 · The pricing bubble may have burst for several insulin products, but similar pricing bubbles for many other brand-name drugs continue to harm patients who need these drugs. Policy makers should consider additional opportunities to improve transparency and ensure the affordability of prescription drugs.
for brand-name drugs, and eliminating anticompetitive pay-for-delay arrangements that curtail access to lower-cost alternatives can make medications more affordable for people with diabetes.
16 Ιουν 2023 · The mean net price of short-acting insulin products faced by payers increased at an annual rate of 5.6% from 2012 to 2017 but then decreased from 2018 to 2019, resulting in an annual net growth of 3.4% across the study period. Mean commercial discounts increased from 37.9% of list price in 2012 to 66.1% in 2019.
We designed formulae for estimating competitive but profitable prices for insulin biosimilars, based on the cost of API and excipients, costs of formulation into phials, development and regulatory cost, and a margin to account for operating expenditures and profit.
11 Σεπ 2020 · Rebates and discounts. Insulin provides an instructive case study of the major impact of rebates and discounts (14). Working on behalf of health plans and insurance companies, pharmacy benefit managers (PBMs) often negotiate discounted prices that are below a drug’s list price (Fig. 1A).
23 Ιουν 2020 · One way of lowering the cost of prescription drugs and to reduce drug shortages is nonprofit generic manufacturing. This can be set up and run by governments, or by nonprofit or philanthropic...
